Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Eagle Ridge Investment Management

Eagle Ridge Investment Management boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 17.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,712 shares of the company’s stock after acquiring an additional 562 shares during the quarter. Eagle Ridge Investment Management’s holdings in Novo Nordisk A/S were worth $384,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in NVO. Westside Investment Management Inc. lifted its holdings in Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at $2,408,000. Lazard Asset Management LLC lifted its holdings in Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after purchasing an additional 964,640 shares in the last quarter. CENTRAL TRUST Co lifted its holdings in Novo Nordisk A/S by 111.6% in the 3rd quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after purchasing an additional 3,166 shares in the last quarter. Finally, Ieq Capital LLC raised its holdings in shares of Novo Nordisk A/S by 136.6% during the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock worth $2,498,000 after acquiring an additional 15,860 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.2 %

Shares of Novo Nordisk A/S stock traded down $0.24 on Monday, reaching $126.61. 1,341,506 shares of the company were exchanged, compared to its average volume of 4,755,698. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a market cap of $568.17 billion, a P/E ratio of 46.99, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock’s 50 day moving average price is $126.86 and its 200-day moving average price is $112.21.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. UBS Group assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Finally, BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.